Saturday, 31 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· November 25, 2025

Woodward outlines 7–12% sales growth target and $1.8B share repurchase plan as automation, aerospace wins drive 2026 outlook

View original at seekingalpha.com
Woodward outlines 7–12% sales growth target and $1.8B share repurchase plan as automation, aerospace wins drive 2026 outlook Earnings Call Insights: Woodward, Inc…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Woodward is still experiencing some supplier performance shortfalls but progress is being made in stabilizing the supplier network

    80% confidence

  • Fiscal 2026 guidance positions Woodward to meet or exceed long-term sales and earnings commitments for 2024-2026 established at last Investor Day

    80% confidence

  • 2025 was another remarkable year for Woodward with record annual revenue exceeding $3.5 billion

    80% confidence

  • Woodward has clear line of sight on LEAP engine purchase orders and aftermarket demand

    80% confidence

  • Woodward is focused on improving fundamentals and expects teams to accelerate improvements in flow and productivity

    80% confidence

  • The EPS guidance for 2026 includes assumptions for new share repurchases

    80% confidence

  • Net sales for Q4 2025 totaled $995 million, an increase of 16%, and full year 2025 sales were $3.6 billion, up 7%

    80% confidence

  • Commercial aftermarket sales grew $50 million from 2024 to 2025, with some portion representing normal growth and some representing advanced purchases

    80% confidence

  • OEM destocking could be completed by the end of the second quarter of fiscal 2026

    80% confidence

  • There are no structural barriers to achieving strong aftermarket margins for LEAP and GTF programs

    80% confidence

  • Legacy narrow-body aftermarket is expected to show single-digit growth rates in 2026

    80% confidence

  • Woodward completed its $600 million share repurchase program more than 1 year ahead of schedule in November 2025

    80% confidence

  • The Spartanburg facility has additional capacity beyond A350 requirements but no major investment planned for NSA capacity

    80% confidence

  • The A350 win will raise Woodward's total A350 shipset value to approximately $550,000 once wing spoiler actuator shipments begin in late calendar 2028

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com